Diabetes & Metabolic Market Research Reports 2026 — GCC & MENA Intelligence

Diabetes mellitus anchors the largest chronic disease franchise spend clusters outside oncology. Rising obesity prevalence across Gulf cities is restructuring epidemiology toward earlier insulin resistance, NAFLD / NASH comorbidity, and accelerated microvascular complications even where macrovascular mortality has improved slightly through lipid and pressure control intensification. GLP‑1 receptor agonists (semaglutide dual oral / injectable, tirzepatide dual incretin modality) materially expanded addressable BMI‑linked populations beyond classical diabetes labels, provoking payer stop‑gap policies, prior authorization escalation, and cardiology liaison for heart failure with preserved EF cohorts deriving HFrEF‑like benefits. Sodium‑glucose co‑transporter‑2 inhibitors and finerenone class mineralocorticoid antagonists tightened renal‑cardio protective prescribing heuristics, especially among diabetic kidney disease stage 3b–4 bridging programmes. Insulin basal–bolus paradigms still dominate insulin‑deficient patients; analogues contend with biosimilar glargine and degludec tenders. CGM penetration is uneven but climbs among Type 1 affluent cohorts.